Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | ADAURA clinical trial update

Deborah Doroshow • 23 Sep 2020
ESMO 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib
ADAURA

Deborah Doroshow, MD, PhD, Mount Sinai Medical Center, New York, NY, discusses results from the ADAURA (NCT02511106) clinical trial, which demonstrated a significant decrease in brain metastases with adjuvant osimertinib versus a placebo. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Deborah Doroshow

5:55
CCOS study: disparities in cancer during the COVID-19 pandemic
Deborah Doroshow • 23 Sep 2020

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals